Payment overview · 2025
General Payments
$348.02
17 reported records · 9 companies
Healthcare provider profile · identity verified
Steven Lee Kanner, DO
Allopathic & Osteopathic Physicians|Internal Medicine · WEST PALM BEACH, FL · NPI 1053306969
Verified facts
What the public records show
CMS Open Payments records show Steven Lee Kanner, DO received $348.02 in general payments during 2025 across 17 reported records.
Lilly USA, LLC accounted for 17.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SEROQUEL as an associated drug or biological on 59 records involving 53 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Seroquel by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Mounjaro by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $59.38 | 17.1% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $54.10 | 15.6% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $53.84 | 15.5% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $51.26 | 14.7% | 2 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $41.33 | 11.9% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $25.03 | 7.2% | 1 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $24.76 | 7.1% | 1 | 2025 |
| Forte Bio-Pharma LLC | Unresolved — no canonical attribution shown | $20.13 | 5.8% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $18.19 | 5.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $348.02 | 17 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $72.03 | 4 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $59.38 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $59.38 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $54.10 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $51.26 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $25.03 | 1 | 2025 |
Source payment records
|
|||||
| NALOCET Normalized: nalocet |
Drug | Forte Bio-Pharma LLC | $20.13 | 1 | 2025 |
Source payment records
|
|||||
| PROLATE Normalized: prolate |
Drug | Forte Bio-Pharma LLC | $20.13 | 1 | 2025 |
Source payment records
|
|||||
| TANLOR Normalized: tanlor |
Drug | Forte Bio-Pharma LLC | $20.13 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $17.28 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SEROQUEL open payments reported associated product |
CMS Open Payments — General Payments 59 supporting records · 53 recipient NPIs · example record 1241586771 |
Seroquel · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
46 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 491 | 155 |
| Amlodipine Besylate | Amlodipine Besylate | 397 | 107 |
| Losartan Potassium | Losartan Potassium | 381 | 114 |
| Alprazolam | Alprazolam | 314 | 57 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 305 | 44 |
| Levothyroxine Sodium | Levothyroxine Sodium | 259 | 74 |
| Gabapentin | Gabapentin | 258 | 64 |
| Metformin Hcl | Metformin Hcl | 250 | 75 |
| Simvastatin | Simvastatin | 246 | 72 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 232 | 58 |
| Omeprazole | Omeprazole | 217 | 66 |
| Meloxicam | Meloxicam | 202 | 71 |
| Tamsulosin Hcl | Tamsulosin Hcl | 185 | 55 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 177 | 52 |
| Metoprolol Succinate | Metoprolol Succinate | 175 | 52 |
| Lisinopril | Lisinopril | 147 | 45 |
| Lorazepam | Lorazepam | 146 | 20 |
| Azithromycin | Azithromycin | 145 | 91 |
| Eliquis | Apixaban | 142 | 29 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 140 | 40 |
| Zolpidem Tartrate | Zolpidem Tartrate | 134 | 25 |
| Furosemide | Furosemide | 133 | 39 |
| Hydrochlorothiazide | Hydrochlorothiazide | 133 | 37 |
| Methylprednisolone | Methylprednisolone | 133 | 82 |
| Montelukast Sodium | Montelukast Sodium | 124 | 43 |
| Baclofen | Baclofen | 109 | 38 |
| Pantoprazole Sodium | Pantoprazole Sodium | 109 | 31 |
| Potassium Chloride | Potassium Chloride | 106 | 38 |
| Hydralazine Hcl | Hydralazine Hcl | 104 | 30 |
| Carvedilol | Carvedilol | 100 | 29 |
| Glipizide | Glipizide | 100 | 28 |
| Ibuprofen | Ibuprofen | 98 | 31 |
| Tramadol Hcl | Tramadol Hcl | 98 | 28 |
| Nifedipine Er | Nifedipine | 97 | 30 |
| Metoprolol Tartrate | Metoprolol Tartrate | 93 | 27 |
| Ozempic | Semaglutide | 84 | 17 |
| Allopurinol | Allopurinol | 80 | 22 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 75 | 12 |
| Duloxetine Hcl | Duloxetine Hcl | 73 | 14 |
| Gemfibrozil | Gemfibrozil | 69 | 17 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 69 | 24 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 68 | 35 |
| Diclofenac Sodium | Diclofenac Sodium | 68 | 16 |
| Trazodone Hcl | Trazodone Hcl | 67 | 20 |
| Fluticasone Propionate | Fluticasone Propionate | 64 | 17 |
| Oxycodone Hcl | Oxycodone Hcl | 64 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 63 | 20 |
| Prednisone | Prednisone | 63 | 24 |
| Atenolol | Atenolol | 61 | 17 |
| Clopidogrel | Clopidogrel Bisulfate | 61 | 18 |
| Famotidine | Famotidine | 60 | 18 |
| Alendronate Sodium | Alendronate Sodium | 54 | 15 |
| Pravastatin Sodium | Pravastatin Sodium | 54 | 14 |
| Temazepam | Temazepam | 53 | 11 |
| Ondansetron Hcl | Ondansetron Hcl | 50 | 16 |
| Doxazosin Mesylate | Doxazosin Mesylate | 49 | 12 |
| Tresiba Flextouch U-200 | Insulin Degludec | 49 | suppressed |
| Diazepam | Diazepam | 48 | 12 |
| Jardiance | Empagliflozin | 46 | 15 |
| Lactulose | Lactulose | 46 | 18 |
| Ezetimibe | Ezetimibe | 45 | 19 |
| Sertraline Hcl | Sertraline Hcl | 45 | 13 |
| Citalopram Hbr | Citalopram Hydrobromide | 44 | 13 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 44 | 11 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 44 | 12 |
| Nitroglycerin | Nitroglycerin | 44 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 44 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 43 | 13 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 42 | 20 |
| Warfarin Sodium | Warfarin Sodium | 42 | 11 |
| Xarelto | Rivaroxaban | 42 | 11 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 41 | 22 |
| Escitalopram Oxalate | Escitalopram Oxalate | 41 | 13 |
| Fenofibrate | Fenofibrate | 41 | 11 |
| Spironolactone | Spironolactone | 41 | 12 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 41 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 40 | suppressed |
| Levofloxacin | Levofloxacin | 37 | 24 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 36 | 13 |
| Terazosin Hcl | Terazosin Hcl | 35 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 33 | suppressed |
| Clonazepam | Clonazepam | 32 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 32 | 23 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 31 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 29 | 19 |
| Amoxicillin | Amoxicillin | 28 | 22 |
| Celecoxib | Celecoxib | 28 | suppressed |
| Finasteride | Finasteride | 28 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 28 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 28 | 12 |
| Valsartan | Valsartan | 28 | suppressed |
| Metronidazole | Metronidazole | 26 | 15 |
| Paxlovid | Nirmatrelvir/Ritonavir | 26 | 26 |
| Synthroid | Levothyroxine Sodium | 26 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 25 | suppressed |
| Myrbetriq | Mirabegron | 25 | suppressed |
| Oxycontin | Oxycodone Hcl | 25 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 25 | 11 |
| Glipizide Er | Glipizide | 24 | suppressed |
| Naproxen | Naproxen | 24 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 24 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 24 | suppressed |
| Tiadylt Er | Diltiazem Hcl | 24 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 24 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 23 | suppressed |
| Januvia | Sitagliptin Phosphate | 23 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 22 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 22 | suppressed |
| Entresto | Sacubitril/Valsartan | 22 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 22 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 22 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 21 | suppressed |
| Sucralfate | Sucralfate | 21 | suppressed |
| Bumetanide | Bumetanide | 20 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 20 | suppressed |
| Ondansetron Odt | Ondansetron | 20 | suppressed |
| Risperidone | Risperidone | 20 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 19 | 11 |
| Topiramate | Topiramate | 19 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 19 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 18 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 18 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 18 | 12 |
| Novolog | Insulin Aspart | 18 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 18 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 17 | suppressed |
| Glimepiride | Glimepiride | 17 | suppressed |
| Klor-Con 10 | Potassium Chloride | 17 | suppressed |
| Levemir Flexpen | Insulin Detemir | 17 | suppressed |
| Minoxidil | Minoxidil | 17 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 17 | suppressed |
| Fluconazole | Fluconazole | 16 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 16 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 16 | suppressed |
| Pregabalin | Pregabalin | 16 | suppressed |
| Anastrozole | Anastrozole | 15 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 15 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 15 | suppressed |
| Memantine Hcl | Memantine Hcl | 15 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 15 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 15 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 15 | suppressed |
| Repatha Sureclick | Evolocumab | 15 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 15 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 14 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 14 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 14 | suppressed |
| Seroquel | Quetiapine Fumarate | 14 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 14 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 13 | suppressed |
| Bupropion Xl | Bupropion Hcl | 13 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 13 | suppressed |
| Ketoconazole | Ketoconazole | 13 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 13 | suppressed |
| Mounjaro | Tirzepatide | 13 | suppressed |
| Pentoxifylline | Pentoxifylline | 13 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 13 | suppressed |
| Rybelsus | Semaglutide | 13 | suppressed |
| Tetrabenazine | Tetrabenazine | 13 | suppressed |
| Verapamil Er | Verapamil Hcl | 13 | suppressed |
| Wellbutrin Xl | Bupropion Hcl | 13 | suppressed |
| Belsomra | Suvorexant | 12 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 12 | suppressed |
| Calcitriol | Calcitriol | 12 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 12 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 12 | suppressed |
| Linzess | Linaclotide | 12 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 12 | suppressed |
| Mirtazapine | Mirtazapine | 12 | suppressed |
| Novolog Flexpen | Insulin Aspart | 12 | suppressed |
| Ramipril | Ramipril | 12 | suppressed |
| Thiothixene | Thiothixene | 12 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 11 | suppressed |
| Creon | Lipase/Protease/Amylase | 11 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 11 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 11 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 11 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 11 | suppressed |
| Sotalol | Sotalol Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $348.02 · 17 records | Lilly USA, LLC | AIRSUPRA, CAPLYTA, MOUNJARO, NALOCET, OTEZLA, PROLATE, REPATHA, REXULTI, TANLOR, ZEPBOUND | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error